Embecta Corporation (EMBC)

NASDAQ:EMBC

EMBC

Embecta Corporation

RESEARCH TOOLSreports

Want to see EMBC full AI Analyst Report?

Embecta Corporation (EMBC) Earnings Dates, Call Summary & Reports

107 Followers

Earnings Data

Report Date

Aug 07, 2026

Before Open (Confirmed)

Period Ending

2026 (Q3)

Consensus EPS Forecast

0.27

Last Year’s EPS

1.12

Same Quarter Last Year

Analyst Consensus

Moderate Sell

Based on 3 Analysts Ratings

Earnings Call Summary

Q2 2026

Earnings Call Date:May 05, 2026|

% Change Since:

Earnings Call Sentiment|Negative

The call presents meaningful strategic progress (Owen Mumford acquisition, GLP‑1 B2B traction, brand transition progress, debt repayment and a share buyback authorization) but was dominated by substantial near‑term operational and financial setbacks: large revenue declines (especially in the U.S. and pen needles), sharp margin and EPS guide cuts, a GAAP net loss in the quarter, and material reductions in free cash flow guidance. Management has initiated cost/organization reviews and highlighted actions underway, but the magnitude and persistence of the U.S. share loss and market volume softness create significant short‑term headwinds.

Company Guidance

Embecta narrowed fiscal 2026 revenue guidance to $1.015–$1.035B (prior $1.071–$1.093B), assuming ~ $30M from the Owen Mumford (OM) close (4 months) and implying an organic midpoint ≈ $995M (≈$75M reduction vs prior low end); Q2 revenue was ~$222M (‑14.4% y/y as‑reported, ‑17.4% adj constant currency), with U.S. ~$95M (‑29.4% adj ccy) and International ~$126M (+2.1% reported, ‑4.1% adj ccy). Product declines (adj ccy) were: pen needles ‑20.4%, syringes ‑14.6%, safety ‑2.3%, contract mfg ‑43.2%; pen needles account for ~70% of the $75M guidance reduction (≈$53M: ~ $25M share loss, ~$20M market volume softness, ~$8M inventory/pricing); syringes ≈$13M, alcohol swabs exit ≈$5M, safety ≈$4M. Q2 GAAP gross profit was $127.8M (57.6% margin) vs $164.1M (63.4% prior year); adjusted gross profit $131.8M (59.4%) vs $165.0M (63.7%). Q2 GAAP operating income $35M (15.8%) vs $62.9M (24.3%); adjusted operating income $48.6M (21.9%) vs $81.4M (31.4%). Q2 GAAP net loss $4.1M, EPS ‑$0.07; adjusted net income $16.1M, EPS $0.27 (prior $40.7M, $0.70). Fiscal guidance: adjusted operating margin cut from 29–30% to 22.25–23.25%; adjusted EPS lowered to $1.55–$1.75 (from $2.80–$3.00), including ~ $0.15 OM dilution and ~ $0.10 from a higher adjusted tax rate (≈23% → ≈28%). Cash and leverage: 6‑month free cash flow ≈$47M, repaid ~$75M of Term Loan B, LTM net leverage ~3x (covenant <4.75x); company still targets ~$150M debt repayment in 2026. Free cash flow guidance is $95–$105M (prior $180–$200M), reflecting ≈$40M of one‑time brand transition/OM cash use. OM terms: upfront £100M plus up to £50M performance payments; FY25 OM revenue ~£69.4M; Aidaptus TAM est. ~$2.4B (double‑digit CAGR); OM expected immaterial to FY27 adjusted operating income and accretive thereafter, with high single‑digit ROIC by year 4. Guidance assumes U.S. share loss and market softness persist.

Owen Mumford Acquisition Accelerates Diversification

Acquisition structured as GBP 100M upfront plus up to GBP 50M performance payments; Owen Mumford (OM) had ~GBP 69.4M revenue in FY2025 with ~80% revenue concentrated in U.K. and U.S.; OM brings Aidaptus auto-injector platform (TAM ≈ $2.4B, double‑digit CAGR) and a diversified medical device portfolio. Expected ~4 months of OM contribution to FY2026 revenue (~$30M). Management expects OM to drive medium/long‑term growth, be immaterial to FY2027 adjusted operating income and accretive thereafter, and deliver high single‑digit ROIC by year 4.

Progress on GLP‑1 B2B Pipeline and Commercial Proof‑Points

Pipeline expanded since last quarter: ~40% of identified pharmaceutical partners are now in active contract negotiations or have executed agreements (up from ~33% prior). Partners achieved Canadian approval and a first U.S. FDA tentative approval for a generic semaglutide; several partners launched generic GLP‑1 therapies co‑packaged with embecta pen needles in India. Small‑pack GLP‑1 retail configurations launched in Canada and Australia with planned U.S. rollout.

Brand Transition and New Product Progress

More than 75% of embecta revenue is now represented by products shipped under the embecta label; substantial completion targeted by end of calendar 2026. Market‑appropriate syringes launched commercially in China; new pen needles have regulatory submissions with U.S. FDA, Brazil, and BSI for CE Mark.

Financial Discipline and Liquidity Actions

Repaid approximately $75M of Term Loan B principal in first 6 months and target to repay ~$150M of debt in 2026. Last 12 months net leverage was ~3.0x, comfortably below covenant of 4.75x. Generated ~ $47M free cash flow in the first 6 months and maintain updated FY2026 free cash flow guidance of $95M–$105M (includes ~$40M of one‑time uses). Board authorized up to $100M share repurchase program.

International Performance Largely In Line

International revenue for the quarter was ~$126M: +2.1% reported but -4.1% adjusted constant currency; management states International performed in line with prior outlook and strengths in Latin America, Asia and Canada partially offset China weakness.

Embecta Corporation (EMBC) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

EMBC Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 07, 2026	2026 (Q3)	0.27 / -	1.12	―	―	―
May 05, 2026	2026 (Q2)	0.42 / 0.27	0.7	-61.43% (-0.43)
Feb 05, 2026	2026 (Q1)	0.67 / 0.71	0.65	9.23% (+0.06)
Nov 25, 2025	2025 (Q4)	0.46 / 0.50	0.45	11.11% (+0.05)
Aug 08, 2025	2025 (Q3)	0.78 / 1.12	0.74	51.35% (+0.38)
May 09, 2025	2025 (Q2)	0.53 / 0.70	0.67	4.48% (+0.03)
Feb 06, 2025	2025 (Q1)	0.49 / 0.65	0.61	6.56% (+0.04)
Nov 26, 2024	2024 (Q4)	0.36 / 0.45	0.59	-23.73% (-0.14)
Aug 09, 2024	2024 (Q3)	0.46 / 0.74	0.69	7.25% (+0.05)
May 09, 2024	2024 (Q2)	0.40 / 0.67	0.75	-10.67% (-0.08)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

EMBC Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 05, 2026	$9.25	$3.90	-57.84%
Feb 05, 2026	$11.19	$10.32	-7.75%
Nov 25, 2025	$14.24	$13.21	-7.24%
Aug 08, 2025	$9.98	$11.82	+18.53%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Embecta Corporation (EMBC) report earnings?

Embecta Corporation (EMBC) is schdueled to report earning on Aug 07, 2026, Before Open (Confirmed).

What is Embecta Corporation (EMBC) earnings time?

Embecta Corporation (EMBC) earnings time is at Aug 07, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is EMBC EPS forecast?

EMBC EPS forecast for the fiscal quarter 2026 (Q3) is 0.27.